About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
Our Science
  • nab-Paclitaxel (Albumin-Bound Microtubule Inhibitor)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    The taxanes act by inhibiting microtubule dynamics during cell division.1-5 The pharmacology of paclitaxel is dependent on its delivery vehicle, and various formulations have produced clinically different outcomes.6,7 nab-Paclitaxel uses albumin to deliver paclitaxel.1,2 Albumin is a ubiquitous carrier of biomolecules in the blood, and it may be consumed by growing tumors as a source of nutrients.8-11

    nab-Paclitaxel by Disease State

    nab-Paclitaxel in Solid Tumors

    Post Approval Research
    Breast: Metastatic

    Post Approval Research
    Non-small cell lung: Advanced (First-line)

    Post Approval Research
    Pancreatic: Metastatic (First-line)

    Phase 3
    Pancreatic: Adjuvant

    Post Approval Research
    Gastric: Metastatic (Japan)

    View Trials Investigating nab-Paclitaxel in Solid Tumors
    View Rationale for Clinical Development

    Rationale for Clinical Development

    Preclinical studies in 2 different pancreatic cancer mouse models (mice with human pancreatic cancer xenografts and genetically engineered mice) demonstrated greater anti-tumor activity with nab-paclitaxel plus gemcitabine than with either agent alone.12,13 In each model, administration of nab-paclitaxel increased the intratumoral accumulation of gemcitabine. The investigators who used the xenograft model proposed that nab-paclitaxel accomplished this by disrupting the tumor stroma,12 and the investigators who used the genetic model suggested that the effect was caused by nab-paclitaxel leading to destabilization of a gemcitabine-metabolizing enzyme.13

    View Related Pathways

    References

    1. Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) [package insert]. Summit, NJ: Celgene Corporation; 2014.
    2. Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) [summary of product characteristics]. Uxbridge, UK: Celgene Europe Limited; 2013.
    3. Taxol (paclitaxel) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
    4. Taxotere (docetaxel) [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; 2014.
    5. Taxotere (docetaxel) [summary of product characteristics]. Essex, UK: Aventis Pharma; 2013.
    6. Gardner ER, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:213-218. PMID: 18191625
    7. Gradishar WJ, et al. J Clin Oncol. 2005;23:7794-7803. PMID: 16172456
    8. Peters T Jr. Adv Protein Chem. 1985;37:161-245. PMID: 3904348
    9. Kiessling F, et al. Invest Radiol. 2002;37:193-198. PMID: 11923641
    10. Kratz F. J Control Release. 2008;132:171-183. PMID: 18582981
    11. Kremer P, et al. Anticancer Drugs. 2002;13:615-623. PMID: 12172507
    12. Von Hoff DD, et al. J Clin Oncol. 2011;29:4548-4554. PMID: 21969517
    13. Frese KK, et al. Cancer Discov. 2012;2:260-269. PMID: 22585996